Maze Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAZE research report →
Companywww.mazetx.com
Maze Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease.
- CEO
- Jason V. Coloma
- IPO
- 2025
- Employees
- 125
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.39B
- P/E
- -11.01
- P/S
- 69.26
- P/B
- 3.95
- EV/EBITDA
- -9.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.04%
- Op Margin
- -670.25%
- Net Margin
- -612.71%
- ROE
- -36.63%
- ROIC
- -33.24%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-131,120,000 · -351.04%
- EPS
- $-3.05 · -4020.31%
- Op Income
- $-142,899,000
- FCF YoY
- -250.70%
Performance & Tape
- 52W High
- $53.65
- 52W Low
- $9.73
- 50D MA
- $32.20
- 200D MA
- $32.64
- Beta
- 2.50
- Avg Volume
- 873.77K
Get TickerSpark's AI analysis on MAZE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Coloma Jason V | sell | 1,822 |
| May 15, 26 | Coloma Jason V | sell | 116 |
| May 14, 26 | Bernstein Harold | other | 15,000 |
| May 14, 26 | Bernstein Harold | other | 15,000 |
| May 14, 26 | Bernstein Harold | sell | 15,000 |
| May 4, 26 | Dandekar Atul | other | 5,985 |
| May 4, 26 | Dandekar Atul | other | 5,985 |
| May 4, 26 | Dandekar Atul | other | 8,320 |
| May 4, 26 | Dandekar Atul | other | 8,320 |
| May 4, 26 | HOMCY CHARLES J | other | 7,422 |
Our MAZE Coverage
We haven't published any research on MAZE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MAZE Report →